Trial Profile
Primary and Secondary Prevention of Human Papillomavirus (HPV) Disease in China
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 27 Sep 2023
Price :
$35
*
At a glance
- Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
- Indications Cervical cancer; Human papillomavirus infections
- Focus Therapeutic Use
- 26 Dec 2009 New trial record